ArticleFrontiers in oncology2025
Development and validation of a risk prediction model for distant metastasis in muscle-invasive bladder cancer: a retrospective study integrating SEER data with external validation cohort and biomarker analysis.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bladder cancer (BCa) ranks among the most prevalent cancers in men, with a subset of patients developing distant metastases (DM), resulting in poor prognosis. This study aims to develop and validate a nomogram to predict DM in patients with BCa, utilizing machine learning techniques to identify potential biomarkers. Methods: Clinical data from patients with BCa diagnosed between January 2010 and December 2015 were retrospectively retrieved from the Surveillance, Epidemiology, and End Results (SEER) database and randomly split into a training cohort (n = 1,619) and an internal validation cohort (n = 694). An external validation cohort (n = 112) was obtained from the Affiliated Hospital of Guangdong Medical University between January 2021 and December 2023. Independent risk factors for DM were identified using univariate and multivariate logistic regression analyses and incorporated into the nomogram. Predictive accuracy was evaluated using calibration curves, and the nomogram's discriminative ability was compared with traditional staging systems by calculating the area under the curve (AUC). Results: Tumor size ≥ 3 cm, N stage (N1-N3), and lack of surgery were found to be independent risk factors for DM, all of which were included in the nomogram. ROC curve analysis demonstrated robust predictive performance, with AUC values of 0.732 in the training cohort, 0.750 in the internal validation cohort, and 0.968 in the external validation cohort. Additionally, calibration curves consistently showed good predictive accuracy across all cohorts. Machine learning methods, including LASSO and Random Forest, identified ADH1B as a potential biomarker for BCa, displaying exceptional diagnostic and prognostic performance (AUC = 0.983). Conclusion: This study, based on the SEER database and an external validation cohort, identified independent risk factors for DM in BCa and revealed ADH1B as a novel biomarker, offering new perspectives for clinical prediction and personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.